We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal.
- Authors
Gomez‐Mayordomo, Victor; Montero‐Escribano, Paloma; Matías‐Guiu, Jordi A.; González‐García, Nuria; Porta‐Etessam, Jesús; Matías‐Guiu, Jorge
- Abstract
The role of disease‐modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease‐2019 (COVID‐19) due to the absence of an adequate immune response against the SARS‐CoV‐2. However, therapies that act on immune response could play a protective role by dampening the cytokine‐release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57‐year‐old man with relapsing‐remitting MS treated with fingolimod that showed a reactivation of COVID‐19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV2 infection. Highlights: We report a patient with Multiple Sclerosis presenting COVID‐19 when treated with fingolimod.Hyperinflammation syndrome was observed after fingolimod withdrawal.Discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV‐2 infection.
- Subjects
SARS-CoV-2; COVID-19; FINGOLIMOD
- Publication
Journal of Medical Virology, 2021, Vol 93, Issue 1, p546
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.26279